cd8a 2 bioxcell be0061 2 43 cd8a 2 apc tonbo biosciences 20 1886 u100 2 43 cd8a (Bio X Cell)
Structured Review
Cd8a 2 Bioxcell Be0061 2 43 Cd8a 2 Apc Tonbo Biosciences 20 1886 U100 2 43 Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 661 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cd8a/InVivoMAb+anti-mouse+CD8%CE%B1/pm41555085-357-170-171
Average 97 stars, based on 661 article reviews
Images
Related Articles
Mouse Assay:Article Title: Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. Article Snippet: After 72 h of activation, CD8+ T cell culture supernatants were collected, stored at −20 °C and quantified using mouse TNF ELISA (R&D systems, MTA00B). .. Mice were intraperitoneally injected with 200 μg Article Title: FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models. Article Snippet: The areas positive for PD-1, CD8, and IFNg were quantified using SlideViewer software (version 2.9.0; 3DHISTECH, Budapest, Hungary). .. Mice were intraperitoneally injected with 200 μg (10 mg/ kg) Injection:Article Title: Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. Article Snippet: After 72 h of activation, CD8+ T cell culture supernatants were collected, stored at −20 °C and quantified using mouse TNF ELISA (R&D systems, MTA00B). .. Mice were intraperitoneally injected with 200 μg Article Title: Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis Article Snippet: For neutrophil depletion, CRLM mice were treated with 200 μg anti-IgG (intraperitoneally, every 3 days, clone 2A3, Bio X Cell, RRID: AB_1107769) or 200 μg anti-Ly6G (intraperitoneally, every 3 days, clone 1A8, Bio X Cell, RRID: AB_1107721). .. For CD8 + T-cell depletion, 200 μg Article Title: FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models. Article Snippet: The areas positive for PD-1, CD8, and IFNg were quantified using SlideViewer software (version 2.9.0; 3DHISTECH, Budapest, Hungary). .. Mice were intraperitoneally injected with 200 μg (10 mg/ kg) Article Title: Targeting PRPF19 suppresses lung cancer progression by abrogating cytokinesis and potentiating anti-tumor immunity Article Snippet: .. For CD8 T cell depletion, C57BL/6 mice bearing KP-1 allografts were randomly assigned to groups and injected intraperitoneally (i.p.) with Control:Article Title: Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy. Article Snippet: After 72 h of activation, CD8+ T cell culture supernatants were collected, stored at −20 °C and quantified using mouse TNF ELISA (R&D systems, MTA00B). .. Mice were intraperitoneally injected with 200 μg Article Title: FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models. Article Snippet: The areas positive for PD-1, CD8, and IFNg were quantified using SlideViewer software (version 2.9.0; 3DHISTECH, Budapest, Hungary). .. Mice were intraperitoneally injected with 200 μg (10 mg/ kg) Immune Cell:Article Title: Blocking aryl hydrocarbon receptor remodels myeloid-T cell crosstalk and enhances anti-PD-1 response in the tumor microenvironment. Article Snippet: .. To selectively deplete immune cell subsets, depletion antibodies (400 μg) were administered intraperitoneally twice a week, beginning one day before treatment, as follows: In Vivo:Article Title: Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner Article Snippet: The ICIs were anti-PD-1 (clone RMP1-14), anti-PD-L1 (clone 10F.9G2), and anti-CTLA-4 (clone UC10-4F10-11) (Bio X Cell, NH, USA). .. For in vivo depletion of T cells, 200 μg of Article Title: Annexin A5-engineered nanovaccines synchronize spatiotemporal antigen release with phagocytosis checkpoint blockade for potent in situ cancer immunotherapy. Article Snippet: In situ generation of autologous tumor vaccines from dying tumor cells offers a promising route for personalized cancer immunotherapy, yet is often limited by phosphatidylserine (PS)-mediated immunosuppressive clearance that can restrict downstream immune activation and favor M2-like macrophage polarization.. Here, we report a sequentially orchestrated nanovaccine (NT@ANX5-P) that couples photodynamic therapy (PDT)-induced immunogenic tumor-cell damage with ondemand PS masking to enhance in situ tumor vaccination.. The nanovaccine consists of a photosensitizer core cloaked with genetically engineered tumor cell membranes displaying Annexin A5 (ANX5) and further shielded by a ROS-cleavable PEG layer for circulatory shielding and local light-responsive activation. Tumor Implantation:Article Title: Targeting PRPF19 suppresses lung cancer progression by abrogating cytokinesis and potentiating anti-tumor immunity Article Snippet: .. For CD8 T cell depletion, C57BL/6 mice bearing KP-1 allografts were randomly assigned to groups and injected intraperitoneally (i.p.) with |

